Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

BACKGROUND: CTLA4 blocking monoclonal antibodies provide a low frequency but durable tumor responses in patients with metastatic melanoma, which led to the regulatory approval of ipilimumab based on two randomized clinical trials with overall survival advantage. The similarly fully human anti-CTLA4...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribas, Antoni, Chesney, Jason A, Gordon, Michael S, Abernethy, Amy P, Logan, Theodore F, Lawson, David H, Chmielowksi, Bartosz, Glaspy, John A, Lewis, Karl, Huang, Bo, Wang, Erjian, Hsyu, Poe-Hirr, Gomez-Navarro, Jesus, Gerhardt, Diana, Marshall, Margaret A, Gonzalez, Rene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543342/
https://www.ncbi.nlm.nih.gov/pubmed/23171508
http://dx.doi.org/10.1186/1479-5876-10-236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543342/
https://www.ncbi.nlm.nih.gov/pubmed/23171508
http://dx.doi.org/10.1186/1479-5876-10-236

Ejemplares similares